Pancragen — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

Pancragen

Also known as: Lys-Glu-Asp-Trp, KEDW, H-Lys-Glu-Asp-Trp-NH2, Lys-Glu-Asp-Trp-NH2, tetrapeptide pancragen

Synthetic short peptide / bioregulatory tetrapeptide

Research chemicalLast updated: October 19, 2026Based on 9 peer-reviewed studies

What it is

Pancragen is a synthetic peptide studied in animals and cell cultures for its potential to improve glucose tolerance and protect pancreatic function in aging. Research is limited to laboratory and animal models. No FDA-approved use; primarily studied in Russian longevity research with limited independent replication.

The scientific side

Pancragen (Lys-Glu-Asp-Trp-NH2) is a synthetic tetrapeptide investigated for pancreatic cytoprotective and geroprotective effects. In aged pancreatic cell cultures, it increases expression of differentiation transcription factors for acinar cells (Pdx1, Ptf1a) and islet cells (Pdx1, Pax6, Pax4, Foxa2, NKx2.2). It also stimulates expression of CXCL12 and Hoxa3 differentiation factors in a tissue-specific manner in pancreatic cells. At the molecular level in aged pancreatic cell cultures, it increases expression of matrix metalloproteinases MMP2 and MMP9, serotonin, glycoprotein CD79alpha, antiapoptotic protein Mcl1, and proliferation markers PCNA and Ki67, while decreasing expression of proapoptotic p53. In organotypic tissue culture, it stimulates reparative processes in pancreatic tissue explants at a concentration of 0.05 ng/ml. In animal models of experimental diabetes, it exerts hypoglycemic and endothelioprotective effects.

Class: Synthetic short peptide / bioregulatory tetrapeptide

Administration & storage

Administration
Intramuscular injection — non-human primate studies (PMID: 28509500)Intramuscular injection — non-human primate studies (PMID: 25946840)Intramuscular injection — rat studies (PMID: 18642713)Oral administration — rat studies (PMID: 18642713)
Storage
No storage conditions for Pancragen are described in the reviewed abstracts.
Cautions
Human pharmacokinetic and safety data are absent from the reviewed literature; all dose-finding and efficacy data come from animal studies or a single small human observational study.,The human study does not report adverse events or specify route/dose, precluding assessment of human safety profile.,Intramuscular injection carries inherent risks (infection, injection-site reactions); sterile technique is essential regardless of compound.,No data on drug interactions, long-term toxicity, or pharmacovigilance for Pancragen were identified in the reviewed abstracts.,Purity and formulation standards of commercially available preparations are not addressed in the reviewed literature.

Legal & regulatory status

US FDA

Not stated in reviewed literature — requires manual verification

WADA

Not stated in reviewed literature — requires manual verification

Health Canada

Not stated in reviewed literature — requires manual verification